Profile cover photo
Profile photo
CrystecPharma Ltd.
2 followers -
CrystecPharma is focused on applying supercritical fluid technology to provide crystal and particle engineering solutions to the pharmaceutical industry
CrystecPharma is focused on applying supercritical fluid technology to provide crystal and particle engineering solutions to the pharmaceutical industry

2 followers
About
Posts

Post has attachment
Crystec apply a modified supercritical anti-solvent (SAS) process in order to high quality dry particles, with the desired particle size, solid-state and physiochemical properties, for optimised drug delivery. Overall, the supercritical fluid (SCF) approach provides an attractive, single step alternative to more conventional options such as micronisation.

This article summarises the pharmaceutical applications of the technology .

For more information about Crystec please visit our website (http://buff.ly/2abiLNn) or contact Serena Wong (serena.wong@crystecpharma.com).
Add a comment...

Post has attachment
Supercritical anti-solvent processes (SAS) have distinct advantages compared with conventional approaches when engineering scalable co-crystals, as described in this article: .

Crystec's SCF technology is a modified version of that described. Each individual particle generated in the SAS process contains a known ratio of more than one API for synergistic delivery or API plus enhancer e.g. to modify the drug release profile.

To learn more about Crystec’s supercritical fluid (SCF) technology, contact Serena Wong (Serena.Wong@crystecpharma.com).
Add a comment...

Post has attachment
Pharmaceutical compounds may need to be coated for a number of reasons including odour- and taste-masking, controlling drug release and enhancing product performance. This review explores the traditional coating methods, as well as emerging novel technologies and their respective advantages and disadvantages: .

Supercritical fluid technology is one alternative to coat particles with minimal solvent residue compared to conventional approaches. To learn more about Crystec’s capabilities, contact Serena Wong (Serena.Wong@crystecpharma.com).
Add a comment...

Post has attachment
70,000 people globally are affected by cystic fibrosis (CF), a condition requiring complex monitoring and personalised treatment plans based on specific needs.

This report reviews the current and future of CF therapies, including pharmaceutical agents, device, regimens along their limitations. To read the full article, please click here: .

Ultimately, a key challenge to overcome is how to deliver inhalable particles to an already compromised lung. This is where we hope Crystec's SCF technology can make a difference.
Add a comment...

Are you heading to CPhI China in Shanghai from 21st to 23rd June? Crystec are also attending and would be delighted to meet companies who are interested in exploring applications of our modified supercritical fluid (Mod-SCF) technology to help overcome challenges with your compounds in development. To book an appointment with us, email Xiaowei Du (Xiaowei.du@crystecpharma.com).
Add a comment...

Crystec still has some appointments available at next week’s BIO Convention in San Francisco.

Crystec are keen to meet with companies looking to improve bioavailability, identify new solid state forms, or address stability issues with their products in development. If you would like to learn more about how our modified supercritical fluid (Mod-SCF) technology can help to optimise the delivery of small and large molecules, please book an appointment with us through the partnering system or email Serena Wong (Serena.Wong@crystecpharma.com).

We look forward to meeting everyone next week.
Add a comment...

Post has attachment
More than 14 million adults in the UK currently suffer from some form of continence. The social and physical impacts associated with this debilitating condition in women are explored in this article: .

At Crystec, we aim to develop new and more effective therapies. Our lead development programme is a fast-acting urinary incontinence therapy that empowers patients to manage their condition proactively and improve their quality of life.

To learn more about our current drug development programmes, please contact Serena Wong (Serena.Wong@crystecpharma.com).
Add a comment...

Crystec still has some appointments available at next week’s BIO Convention in San Francisco.

Crystec are keen to meet companies looking to improve bioavailability, identify new solid state forms, or address stability issues with their products in development. If you would like to learn more about how our modified supercritical fluid (Mod-SCF) technology can help to optimise the delivery of small and large molecules, please book an appointment with us through the partnering system or email Serena Wong (Serena.Wong@crystecpharma.com). We look forward to meeting everyone next week.
Add a comment...

Post has attachment
This paper written by Martin Viertelhaus and Andreas Hafner explores the advantages of co-crystals and whether they are a solution for the next generation of medicines. Click here to download the full article: http://buff.ly/1XnL4d0.

Crystec's supercritical fluid (SCF) technology can generate co-crystals and composite particles, incorporating more than one API or an API plus enhancer to facilitate membrane transport. Unlike more conventional approaches, the SCF process for manufacturing co-crystals is readily scalable. For more information, contact Serena Wong (Serena.Wong@crystecpharma.com
Add a comment...

Crystec are attending BIO in San Francisco from the 6th-9th June. If you are interested in our supercritical fluid (SCF) technology and how it can help to address drug bioavailability and stability challenges, please arrange to meet with us through the Business Partnering system or contact Serena Wong (Serena.Wong@crystecpharma.com). We also welcome licensing interest in our novel products for urge incontinence and fungal infections.
Add a comment...
Wait while more posts are being loaded